
We zzso evaluated the clinical and zzso responses to zzso therapy zzso with zzso zzso zzso infusions in 5 patients zzso zzso zzso with type 3 zzso zzso The patients were followed for up to 5 zzso zzso dosage ranged from 120 to zzso zzso of body zzso zzso manifestations of the disease zzso in all zzso Neurological deficits remained stable in 3 patients and slightly improved in zzso One patient developed zzso zzso zzso deterioration occurred in 1 patient and zzso deterioration in zzso zzso zzso fluid zzso samples were obtained during the first 3 years of treatment in 3 patients and were analyzed for zzso markers of disease zzso zzso and zzso levels were not elevated in these zzso whereas zzso and zzso acid were elevated in 2 zzso Progressive decrease in the zzso levels of these latter zzso markers during 3 years of treatment implies a decreased number of zzso cells in the cerebral zzso zzso Similar changes were not observed in the patient who had a poor neurological zzso In conclusion, zzso reverses systemic manifestations of type 3 zzso disease and appears to reduce the burden of zzso cells in the zzso compartment in some zzso 

